Dolphin
Senior Member (Voting Rights)
Comment: unfortunately the information that is freely available is not very informative in terms of the substance of this piece.
Abstract only
Volume 28, Issue 6, Supplement 1S77July 2025
Affiliations & Notes
1University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2Hamburg Center for Health Economics (HCHE), Hamburg, Germany
Show Outline
ME/CFS is a chronic neurological disease with the hallmark symptom of post-exertional malaise (PEM) alongside other symptoms such as fatigue, cognitive impairment, and pain. Its etiology is still unknown; the diagnosis relies on international consensus criteria. As no curative therapy exists, treatment focuses on symptom management. The prevalence in the US is estimated at 0.42% of the adult population with women being affected three times as often as men. As many Post-COVID patients meet the ME/CFS diagnostic criteria, a rise in prevalence is expected. Besides the severe symptoms, ME/CFS can lead to negative economic consequences. Therefore, this review aims to answer the question: What is known about the burden of ME/CFS?
Abstract only
Volume 28, Issue 6, Supplement 1S77July 2025
EE81 Burden of Disease in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Patricia Vester, M.Sc.<a>1</a> ∙ Stefanos Boudouroglou-Walter, M.Sc.<a>1</a> ∙ Jonas Schreyögg, Prof. Dr.<a>2</a> ∙ Chantal Wieting, B.Sc.<a>1</a> ∙ Christine Blome, PD Dr.<a>1</a>Affiliations & Notes
1University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
2Hamburg Center for Health Economics (HCHE), Hamburg, Germany
Show Outline
ME/CFS is a chronic neurological disease with the hallmark symptom of post-exertional malaise (PEM) alongside other symptoms such as fatigue, cognitive impairment, and pain. Its etiology is still unknown; the diagnosis relies on international consensus criteria. As no curative therapy exists, treatment focuses on symptom management. The prevalence in the US is estimated at 0.42% of the adult population with women being affected three times as often as men. As many Post-COVID patients meet the ME/CFS diagnostic criteria, a rise in prevalence is expected. Besides the severe symptoms, ME/CFS can lead to negative economic consequences. Therefore, this review aims to answer the question: What is known about the burden of ME/CFS?